Avandia may come with stronger warnings, sources say

10/24/2007 | Wall Street Journal (free content), The

The FDA is pushing for a "black box" warning on labels of GlaxoSmithKline's diabetes drug Avandia to include information about the treatment's heart attack risk, officials familiar with the issue say. A GSK spokeswoman said the drug giant is "working diligently with the FDA to finalize the label" on Avandia, which already carries a "black box" warning about heart failure.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance & Ethics, US Operations
Bristol-Myers Squibb
Princeton, NJ
Manager, Educational Programs
The Food and Drug Law Institute
Washington, DC, DC
Global Medical Safety Director - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Compliance Manager/Sr. Compliance Manager- Auditing
South San Francisco, CA